Mission Statement, Vision, & Core Values (2026) of Jafron Biomedical Co.,Ltd.

Founded in 1989, Jafron Biomedical Co., Ltd. has grown into a global leader in blood purification technology with a market value of about $7 billion, operating 183 offices across China and five global service centers while its HA series hemoperfusion cartridges are used in over 8,000 hospitals across more than 90 countries and account for roughly 5 million clinical applications annually; anchored by a mission to expand access to advanced therapies, break foreign technological monopolies, and apply biotechnology and cell therapy to improve patient outcomes, Jafron pairs core values of integrity, excellence, innovation, and collaboration with certified quality standards (CE, ISO, Chinese GMP), a historic first-developing the world's first hemoadsorption cartridge for uremic patients in 2004-and an ambitious vision, including the near-complete 95,318-sqm Jinding Industrial Park and a goal to build a unique whole-value chain of "product + services + finance + Internet" in blood purification by 2025, all driving readers to explore how these strategic pillars translate into tangible healthcare impact

Jafron Biomedical Co.,Ltd. (300529.SZ) - Intro

• Founded: 1989
• Market value: ~ $7 billion
• Domestic offices: 183
• Global service centers: 5
• Hospitals served: >8,000 in 90+ countries
• Annual clinical applications: ~5,000,000
• Key certifications: CE, ISO, Chinese GMP
• Major facility: 95,318 sqm Jinding Industrial Park (completion 2023)

• Patient First - prioritizing safety, efficacy, and accessibility for patients worldwide.
• Innovation - sustained R&D investment to lead hemoadsorption breakthroughs.
• Quality & Compliance - adherence to international standards (CE, ISO, GMP) throughout design and production.
• Global Responsibility - expanding access through international service centers and partnerships.
• Integrity & Transparency - ethical conduct across clinical, commercial, and corporate activities.

• R&D: Continuous development of next-generation hemoadsorption cartridges and related consumables.
• Manufacturing scale-up: Completion and commissioning of the 95,318-sqm Jinding Industrial Park to increase capacity and quality control.
• Clinical reach: Extending HA series deployment beyond 8,000 hospitals and growing annual applications beyond 5 million.
• Regulatory & quality: Maintaining and expanding international certifications to support market access.

Jafron Biomedical Co.,Ltd. (300529.SZ) - Overview

• Primary mission: Develop and commercialize advanced biological and medical technologies that measurably improve patient outcomes.
• R&D emphasis: Biotechnology, cell therapy, extracorporeal blood purification, immunomodulation and related platform technologies.
• Access and equity: Expand availability of advanced treatments via payment innovation, primary-care capacity building, and supply-chain coordination.
• Strategic objective: Reduce dependence on foreign technology by accelerating domestic innovation and manufacturing capabilities.
• Patient-centric goal: Elevate patients' quality of life through evidence-based therapies and integrated clinical solutions.

• Innovation pipeline: Prioritize platform technologies (cell therapy, blood-purification) and accelerate clinical translation with multi-center trials and regulatory submissions.
• Capacity building: Support primary healthcare through training programs, deployment of simplified technologies, and regional service networks.
• Payment innovation: Pilot reimbursement pathways, hospital payment models, and partnerships with payers to improve patient access.
• Vertical integration: Strengthen domestic supply chains and manufacturing to reduce dependence on foreign critical components and technologies.
• Commercial scale-up: Expand domestic hospital adoption and export footprint to diversify revenue and clinical impact.

• Clinical evidence: Multiple registered clinical studies demonstrating efficacy of core blood-purification systems in sepsis and critical care settings.
• Regulatory progress: Approvals and clearances in China and CE/other export certifications for selected devices and consumables.
• Commercial traction: Significant installed base in tertiary and regional hospitals, with growing penetration in community-level facilities.
• Financial discipline: Sustained R&D investment (~6% of revenue) while maintaining positive net profitability to support growth.

Jafron Biomedical Co.,Ltd. (300529.SZ) - Mission Statement

• Deliver safe, effective blood purification products and services that materially improve patients' quality of life.
• Build an integrated value chain of product + services + finance + Internet by 2025 to accelerate adoption and access.
• Continuously invest in R&D and regulatory excellence to maintain global standards (CE, ISO, CN-GMP) and to pioneer new clinical technologies.
• Scale manufacturing capacity responsibly via the Jinding Industrial Park to meet global demand while ensuring quality and cost-effectiveness.

Key strategic pillars supporting the mission:

• Technology leadership - commercialized the world's first hemoadsorption cartridge for uremic patients in 2004 and sustained iterative product development since.
• Manufacturing scale - completion of the Jinding Industrial Park in 2023 to become a world-class production base for blood purification equipment and consumables.
• Quality and compliance - maintaining CE, ISO and Chinese GMP certifications across major product lines.
• Integrated ecosystem - combining devices, clinical services, financing solutions and digital platforms to deliver end-to-end value to hospitals, clinicians and patients.

• Milestones: 2004 - world's first hemoadsorption cartridge for uremic patients; 2023 - Jinding Industrial Park becomes operational; 2025 - target integrated value-chain realization.
• Patient impact metrics: products deployed across thousands of hospital sites with hundreds of thousands of treatments annually (scale expanded significantly after 2023 park commissioning).

Core organizational values that operationalize the mission:

• Patient-centered innovation - prioritize safety, efficacy and measurable improvements in patient outcomes.
• Quality and compliance - adhere to international and national standards in design and manufacturing.
• Collaboration - partner with clinicians, payers and technology partners to scale access.
• Sustainability - optimize resource use and supply chains to ensure long-term, reliable access to therapies.

Jafron Biomedical Co.,Ltd. (300529.SZ) - Vision Statement

• Integrity: rigorous compliance, transparent reporting, and ethical clinical practice.
• Excellence: clinically driven product design, robust quality management systems, and ISO/CE-level certifications informing production standards.
• Innovation: sustained R&D investment to convert basic science into scalable therapeutic platforms.
• Collaboration: partnerships with hospitals, academic centers, and global distributors to accelerate adoption and evidence generation.

• Core technological thrust: development of functional cellular products (e.g., autologous/allogeneic cell platforms) and advanced hemoperfusion/hemofiltration devices targeting sepsis, cytokine storm management, and chronic inflammatory conditions.
• Clinical reach: prioritized deployment in ICU, nephrology, hepatology, oncology-supportive care, and regenerative-surgery settings.
• Quality & safety commitments: systematic post-market surveillance, clinical registry frameworks, and GMP-compliant manufacturing footprint to ensure product traceability and patient safety.

• Scale clinically validated products: expand indications and generate high-quality evidence through randomized and real-world studies.
• Accelerate product pipeline: shorten time-to-market for functional cellular products and next-gen filtration cartridges via platform engineering and modular manufacturing.
• Maintain regulatory rigor: align product dossiers with NMPA, CE, and other regional requirements to facilitate broader market access.
• Foster ecosystem partnerships: co-develop protocols with tertiary hospitals and integrate devices into standardized treatment pathways.